NCT07006649 CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma Elasticum
| NCT ID | NCT07006649 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Angers |
| Condition | Pseudoxanthoma Elasticum |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-11-28 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-11-28 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study sets out to compare choriocapillaris flow deficits between healthy control subjects and patients with pseudoxanthoma elasticum. Pseudoxanthoma elasticum (PXE) is a rare, incurable hereditary disease caused by genetic mutations. The condition is characterised by excessive tissue mineralisation, which can result in a range of dermatological, vascular, and ophthalmological complications. Among these complications is the potential for visual impairment. The management of this condition is focused on the treatment of its complications. Degeneration of the retina and the choroid (the layer responsible for ensuring its vascularisation) occurs in the eye, resulting in premature degeneration. We would like to study the premature alteration of these structures, which could subsequently be used as an objective marker of the evolution of pseudoxanthoma elasticum.
Eligibility Criteria
Inclusion Criteria: * Participant not afflicted by the disease under investigation and without ophthalmological pathology * Person matched in age (+/- 5 years) and gender to a case (patient with PXE in pre-atrophic stages included in the PXE cohort) * Signature of informed consent for participation in the protocol * Adult at time of inclusion Criteria for non-inclusion of research subjects * Known ophthalmological diseases (maculopathy, glaucoma, optic neuropathy, retinopathy whatever the aetiology) * Known severe myopia, defined by a sphere \> - 6 dioptres * Diabetic subject * Unable to carry out the ophthalmological examinations of the study * Pregnant, breast-feeding or parturient woman * Person undergoing psychiatric care under constraint * Person subject to a legal protection measure * Person not affiliated or not benefiting from a social security scheme Exclusion Criteria: * Ophthalmic pathology (maculopathy, glaucoma, optic neuropathy, retinopathy, whatever the etiology) discovered during the ophthalmic workup * AngioOCT examination inexploitable (artifact and/or image quality less than 50/100 even after pupillary dilation) * Severe myopia (sphere \> - 6 dioptres) discovered during the ophthalmic workup. Case inclusion critera : * Patient diagnosed with pseudoxanthoma elasticum, defined according to Plomp's criteria: two out of three features related to PXE: (1) two pathogenic mutations in the ABCC6 gene, and/or (2) disease-specific dermatological changes and/or (3) disease-specific ocular changes; * Included in the PXE cohort ; * With pre-atrophic damage, i.e. at least one eye without choroidal neovessels on OCT-A, without previous intravitreal injection of anti-VEGF, and without major retinal atrophy (less than 2 papillary diameters); * who have had an angiographic OCT (performed during follow-up consultations) with usable results (no artifacts and image quality of 50/100 or better) ; * patient's non-objection to participation in a study Case criteria for non-inclusion : * Other known ophthalmological pathology (maculopathy, glaucoma, optic neuropathy, retinopathy of any etiology) * Severe myopia, defined by a sphere \> - 6 dioptres * Diabetic subject
Contact & Investigator
Laurie MOUROZEAU, Doctor
PRINCIPAL INVESTIGATOR
University Hospital, Angers
Frequently Asked Questions
Who can join the NCT07006649 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pseudoxanthoma Elasticum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07006649 currently recruiting?
Yes, NCT07006649 is actively recruiting participants. Contact the research team at Laurie.Mourozeau@chu-angers.fr for enrollment information.
Where is the NCT07006649 trial being conducted?
This trial is being conducted at Angers, France.
Who is sponsoring the NCT07006649 clinical trial?
NCT07006649 is sponsored by University Hospital, Angers. The principal investigator is Laurie MOUROZEAU, Doctor at University Hospital, Angers. The trial plans to enroll 60 participants.